VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | The role of FLOT2 in CML progression & how it differs from AML

Daniela Krause, MD, Georg-Speyer-Haus, Goethe University, Frankfurt, Germany, outlines the role of the lipid raft-associated protein flotilin 2 (FLOT2) in chronic myeloid leukemia (CML) progression. Prof. Krause explains that FLOT2 deficiency has been shown to be associated with prolonged survival in CML but not in acute myeloid leukemia (AML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Support from Merck KGaA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter